<DOC>
	<DOC>NCT00717860</DOC>
	<brief_summary>The purpose of this study is to investigate the safety and efficacy of MK0991 in patients with deep-seated mycoses.</brief_summary>
	<brief_title>A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<mesh_term>Micafungin</mesh_term>
	<criteria>Japanese Patients In Whom A Causative Fungus Is Detected Before Treatment With The Study Drug Or Patients With Strongly Suspected DeepSeated Fungal Infection Due To Candida species (Spp.) Or Aspergillus Spp. Patients With Mycoses Other Than Ones Due To Candida Spp. Or Aspergillus Spp. Patients Who Will Receive Other Systemic Antifungal Agents For The First Time In Screening Period.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>